ArticleCureus2024

Impact of Erenumab on Migraine Disability: A Three-Month MIDAS (Migraine Disability Assessment Scale) Score Analysis at Dubai Health Facilities.

Ali Almarzooqi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.